PD153035 is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is widely used in research settings to study EGFR signaling pathways, which play critical roles in cell proliferation, survival, and differentiation. Due to its high specificity, PD153035 is employed to investigate the molecular mechanisms underlying cancer development, particularly in tumors driven by EGFR overexpression or mutation. In oncology research, PD153035 helps evaluate the efficacy of EGFR inhibition in suppressing tumor growth in vitro and in animal models. It has shown activity in reducing the growth of non-small cell lung cancer, glioblastoma, and other epithelial cancers where EGFR dysregulation is a key factor. Additionally, it serves as a tool compound for validating new therapeutic targets and for studying resistance mechanisms to EGFR-targeted therapies. Beyond cancer, PD153035 has been used in studies exploring EGFR's role in wound healing, inflammation, and tissue regeneration. Its ability to cross cell membranes makes it suitable for cellular and in vivo experiments, supporting its use in pharmacological and biochemical assays aimed at understanding signal transduction and developing new targeted treatments.